Today: 8 June 2026
Browse Category

NYSE:ABT 26 January 2026 - 16 April 2026

US Stock Market Today: S&P 500, Nasdaq Hit Record Highs as Wall Street Bets on Ceasefire, Earnings

US Stock Market Today: S&P 500, Nasdaq Hit Record Highs as Wall Street Bets on Ceasefire, Earnings

The S&P 500 and Nasdaq hit new intraday highs Thursday, with the S&P 500 up 0.27% and the Nasdaq rising 0.38% by late morning. Strong earnings from major banks and tech optimism fueled gains, while oil prices climbed as traders doubted progress in Middle East talks. Jobless claims fell to 207,000, but U.S. manufacturing output slipped 0.1% in March.
16 April 2026
········
SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

Schwab U.S. Dividend Equity ETF paid a $0.2569 per-share dividend for March, up 3.3% from last year, and finished a major reshuffle in its annual index reset. SCHD drew $4 billion in Q1 inflows as U.S. dividend funds saw their strongest start since 2020. The fund now holds 104 stocks, with Chevron and ConocoPhillips still its largest positions. Health care and tech exposure rose, while energy and materials fell.
6 April 2026
···········
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

Schwab’s U.S. Dividend Equity ETF (SCHD) increased health care holdings to 18.5% in its annual rebalance, adding Abbott Laboratories and UnitedHealth Group near the top at about 3.8% each. SCHD attracted $4 billion in Q1 as U.S. dividend funds pulled in $24.1 billion, the highest first-quarter inflow in four years. SCHD closed at $30.48 Monday, up 0.13%.
30 March 2026
············
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott Laboratories shares fell 0.6% to $108.77 after the FDA issued a warning letter over quality-control lapses in its FreeStyle Libre glucose monitors. The FDA said Abbott released devices without required accuracy tests and failed to ensure specs were met by third-party manufacturers. Abbott has 15 business days to respond. Shares had dropped as much as 2.9% earlier in the session.
3 February 2026
·
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott shares slipped 0.3% to $109.00 after Barclays cut its price target to $142 from $169, citing ongoing pressure in nutrition and diagnostics. About 6.1 million shares traded as investors awaited updates from medical meetings and the Feb. 13 dividend. The stock has struggled since missing revenue estimates and warning of slower nutrition growth in late January.
2 February 2026
·
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott shares closed Friday up 3.03% at $109.30, rebounding after post-earnings losses earlier in the week. Brokerages lowered price targets, citing nutrition segment challenges and a cautious outlook for early 2026. Investors are watching for updates on the Exact Sciences acquisition, expected to close in the second quarter. The S&P 500 and Dow both fell on the day.
1 February 2026
·
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories shares closed up 3% at $109.30 Friday after trading between $105.72 and $109.47. CEO Robert B. Ford bought 18,800 shares on January 23 for about $2 million. The company forecast 2026 organic sales growth of 6.5%–7.5% and reaffirmed plans to acquire Exact Sciences in Q2. Abbott’s Q1 earnings and nutrition outlook remain under pressure after missing revenue estimates.
31 January 2026
·
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott shares fell 2.1% to $106.05 Wednesday after CEO Robert Ford bought about $2 million in stock through a family trust, according to an SEC filing. The stock has dropped 12% in five sessions following a disappointing earnings report and a price target cut by Argus. Investors are watching for updates at major medical conferences starting Jan. 29 in New Orleans.
29 January 2026
·
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories shares fell about 2% to $106.12 Wednesday after Argus cut its price target to $140, following last week’s earnings warning. CEO Robert Ford bought 18,800 shares on Jan. 23 at an average $107.13, according to an SEC filing. The broader healthcare sector slipped ahead of the Federal Reserve’s rate decision. Abbott cited weak nutrition and diagnostics sales and higher costs for its recent profit miss.
28 January 2026
·
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
····
Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott Laboratories shares fell 1.2% to $107.49 by midday Tuesday after CEO Robert Ford disclosed buying 18,800 shares at an average price of $107.13. The drop followed a weak quarterly outlook and missed revenue targets, with investors watching ongoing challenges in Abbott’s nutrition segment. Health-care stocks broadly declined after a proposed near-flat Medicare Advantage payment rate for 2027.
27 January 2026
·
Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott Laboratories shares rose about 1% Monday after CEO Robert Ford bought nearly $2 million in stock, acquiring 18,800 shares at an average $107.13 each. The stock traded at $108.49 midday. Ford now holds 253,305 shares directly and 216,203 through a trust. The purchase follows last week’s earnings report and guidance update, with Q4 adjusted earnings at $1.50 per share on $11.459 billion in sales.
26 January 2026
·
1 2 3

Stock Market Today

  • Nvidia Stock Poised for Growth, Targeting $300 by 2027
    June 8, 2026, 11:14 AM EDT. NVIDIA delivered a record Q1 FY27 with $81.6 billion revenue, up 85.2%, driven by a 92% surge in its Data Center segment. Despite strong fundamentals and a 214.5% earnings growth projection, shares trade modestly at $205.10, partly due to market volatility and China-related restrictions. Wall Street's average price target stands at $298.42, suggesting 45% upside, while an internal model estimates a more cautious $255.67 by mid-2027. Achieving $300, implying a forward price-to-earnings ratio of 38, hinges on sustained AI-driven demand, backed by $119 billion in supply contracts and an $80 billion buyback plan. Challenges include potential hyperscaler capital expenditure slowdowns and ongoing geopolitical tensions. Overall, NVIDIA trades attractively at 26 times forward earnings amid rapid revenue and earnings growth, facing sentiment hurdles more than financial ones.

Latest articles

Oil Pops, Tech Moves Sideways as Iran-Israel Tensions Flare

Oil Pops, Tech Moves Sideways as Iran-Israel Tensions Flare

8 June 2026
Wall Street’s main indexes rebounded at Monday’s open as chip stocks recovered and easing Middle East tensions offset an early oil price jump; the Dow rose 0.26%, S&P 500 gained 0.77%, and Nasdaq advanced 1.38%, after Friday’s tech rout and amid concerns the Fed may keep policy tighter for longer following strong U.S. jobs data.
Wall Street Hit With New AI Bubble Jitters as Doubts Grow

Wall Street Hit With New AI Bubble Jitters as Doubts Grow

8 June 2026
U.S. stocks rebounded Monday after a $2 trillion wipeout led by chip stocks, but investors are questioning whether massive AI spending can deliver durable earnings as strong jobs data dims hopes for Fed rate cuts, raising pressure on high-priced growth shares.
Mortgage Rates Fall but Buyers Still Face Pressure

Mortgage Rates Fall but Buyers Still Face Pressure

8 June 2026
U.S. mortgage rates dipped to 6.48% from 6.53%, offering slight relief as the housing market faces falling listing prices—down 2.4% year-over-year to $429,500—but persistent high borrowing costs and strong jobs data threaten to push rates higher, risking further pressure on home sales and affordability.
QQQ Slides 4.8% But Options Market Sends Mixed Signals

QQQ Slides 4.8% But Options Market Sends Mixed Signals

8 June 2026
QQQ jumped 1.6% to $716.47 Monday after a 4.8% drop, as options data showed traders cautious but not panicked; the rebound follows a tech selloff sparked by Fed rate fears and AI spending doubts, while upcoming Nasdaq-100 rebalancing and new ETF competition add uncertainty for investors.
SOXL’s 433% Rally in AI Chip Sector Meets Sharp Pullback

SOXL’s 433% Rally in AI Chip Sector Meets Sharp Pullback

8 June 2026
SOXL surged nearly 15% to $209.62 Monday after last week’s 30.5% plunge, as chip stocks rebounded from a $1.3 trillion rout; leveraged ETF swings highlight the risks of daily resets, with Direxion and regulators warning these funds are trading tools, not long-term bets, especially as investors eye upcoming inflation data and Fed meetings.
Go toTop